BNT314 not checked

BioNTech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Colorectal Cancer, Advanced Malignant Solid Tumor
Main trialPhase 1/2
“This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and chemotherapy in participants with metastatic colorectal cancer (mCRC).”In the company’s words, NCT07079631 on ClinicalTrials.gov

Other drugs for Metastatic Colorectal Cancer

All 392 drugs for Metastatic Colorectal Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Dec 2030 A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Phase 1Active, not recruiting 18 Aug 2026 Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BNT314

Following is part of Solo: you see every change to BNT314 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in